REGENXBIO Unveils Groundbreaking Findings at MDA 2026 Conference on Duchenne Therapy
On March 4, 2026, REGENXBIO Inc., a prominent biotechnology firm focused on gene therapy, announced that it will present significant findings related to its investigational gene therapy RGX-202 for Duchenne muscular dystrophy (DMD) at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. This prestigious event is set to take place from March 8 to 11 in Orlando, Florida.
REGENXBIO's presentations at the conference will delve into both preclinical and Phase I/II clinical trial data concerning RGX-202. The aim is to unveil insights into the therapy's safety, biomarker responses, and its functional efficacy. One of the major highlights will be a podium presentation outlining the interim findings from the Phase I/II study. This session, titled 'RGX-202, An Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Interim Phase I/II Clinical Data (P432 O)', will take place on March 11 at 11:45 a.m. ET, with Dr. Carolina Tesi Rocha, a Clinical Professor in Neurology at Stanford Children's Health, serving as the presenter.
In addition to the podium presentation, a poster presentation will be showcased by Dr. Steven Foltz, a Principal Scientist in Gene Therapy Research at REGENXBIO. This presentation will cover a groundbreaking study titled 'Microdystrophin with an extended C-Terminal domain protects against pharmacologically induced cardiac damage and remodeling in mdx mice (P173 M)'. This research highlights the potential of the microdystrophin variant in safeguarding cardiac function, providing a new pathway for therapeutic intervention in dystrophin-deficient muscle disorders.
Furthermore, REGENXBIO plans to host an important symposium during the conference, titled 'Advancing Duchenne Gene Therapy Trials in a New Era: Optimizing Design and Interpretation.' Scheduled for March 9 at 12 p.m. ET, this symposium aims to bring together leading experts to discuss the latest advancements in Duchenne gene therapy, focusing on how to optimize trial designs and improve therapeutic outcomes.
REGENXBIO was established in 2009 with a mission to harness the transformative potential of gene therapy to enhance patients' lives. Over the years, the company has made substantial strides in the field of adeno-associated virus (AAV) gene therapy, advancing several late-stage treatments aimed at rare and retinal diseases. RGX-202 is part of this innovative pipeline, along with additional investigational therapies for various conditions, including RGX-121 and RGX-111, developed in collaboration with Nippon Shinyaku, and ABBV-RGX-314, created in collaboration with AbbVie.
With its AAV platform, REGENXBIO has successfully administered therapies to thousands of patients, exhibiting the potential of gene therapy to alter healthcare delivery radically. The company's recent developments signify a promising future of genetic solutions for debilitating conditions, particularly Duchenne muscular dystrophy, which remains an area of vital research attention.
More details regarding these pivotal presentations will be accessible on the Publications section of REGENXBIO's official website following the conference. As gene therapy continues to evolve, REGENXBIO stands at the forefront, championing new explorations that may one day cure rare genetic diseases.
REGENXBIO's presentations at the conference will delve into both preclinical and Phase I/II clinical trial data concerning RGX-202. The aim is to unveil insights into the therapy's safety, biomarker responses, and its functional efficacy. One of the major highlights will be a podium presentation outlining the interim findings from the Phase I/II study. This session, titled 'RGX-202, An Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Interim Phase I/II Clinical Data (P432 O)', will take place on March 11 at 11:45 a.m. ET, with Dr. Carolina Tesi Rocha, a Clinical Professor in Neurology at Stanford Children's Health, serving as the presenter.
In addition to the podium presentation, a poster presentation will be showcased by Dr. Steven Foltz, a Principal Scientist in Gene Therapy Research at REGENXBIO. This presentation will cover a groundbreaking study titled 'Microdystrophin with an extended C-Terminal domain protects against pharmacologically induced cardiac damage and remodeling in mdx mice (P173 M)'. This research highlights the potential of the microdystrophin variant in safeguarding cardiac function, providing a new pathway for therapeutic intervention in dystrophin-deficient muscle disorders.
Furthermore, REGENXBIO plans to host an important symposium during the conference, titled 'Advancing Duchenne Gene Therapy Trials in a New Era: Optimizing Design and Interpretation.' Scheduled for March 9 at 12 p.m. ET, this symposium aims to bring together leading experts to discuss the latest advancements in Duchenne gene therapy, focusing on how to optimize trial designs and improve therapeutic outcomes.
REGENXBIO was established in 2009 with a mission to harness the transformative potential of gene therapy to enhance patients' lives. Over the years, the company has made substantial strides in the field of adeno-associated virus (AAV) gene therapy, advancing several late-stage treatments aimed at rare and retinal diseases. RGX-202 is part of this innovative pipeline, along with additional investigational therapies for various conditions, including RGX-121 and RGX-111, developed in collaboration with Nippon Shinyaku, and ABBV-RGX-314, created in collaboration with AbbVie.
With its AAV platform, REGENXBIO has successfully administered therapies to thousands of patients, exhibiting the potential of gene therapy to alter healthcare delivery radically. The company's recent developments signify a promising future of genetic solutions for debilitating conditions, particularly Duchenne muscular dystrophy, which remains an area of vital research attention.
More details regarding these pivotal presentations will be accessible on the Publications section of REGENXBIO's official website following the conference. As gene therapy continues to evolve, REGENXBIO stands at the forefront, championing new explorations that may one day cure rare genetic diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.